Figure 4:

MR images of acute enhanced lesions in a 32-year-old man with relapsing-remitting MS. A, T1-weighted image acquired after administration of gadolinium chelate and, B, QSM at QSM1. C, T1-weighted image acquired after administration of gadolinium chelate and, D, QSM at QSM2 (3 months later). Two acute enhanced lesions (A, arrows) appeared QSM isointense (B, boxes), which indicated that their susceptibilities were similar to NAWM. Three months later, both changed into QSM hyperintense (D, arrows), which indicated that their susceptibilities increased compared with NAWM. One was still T1 hypointense (C, arrow), the other recovered to normal appearance on images that were T2 weighted, T1 weighted, and T1 weighted after administration of gadolinium chelate (Fig E4 [online]) but appeared hyperintense on QSM (D, black arrow), which suggested that QSM can detect MS lesions that are not detectable on conventional MR images.